BH3 profiling of pretreatment samples from patients with ALL. (A) Mitochondrial response to BAD BH3 (P = .27; 1-tailed t test) or venetoclax (P = .16) are not significant predictors of relapse. (B) Mitochondrial response to the MS1 peptide is the best BH3 profiling predictor of relapse (P = .11). (C) Receiver operator curve (ROC) for 10 μM MS1 as a binary predictor of relapse on venetoclax-based therapy (P = .18; AUC = 0.76). Black line indicates median. Each dot represents an individual patient. AUC, area under the curve.